TriSalus Life Sciences, Inc. filings document operating results, governance actions and capital-structure matters for an oncology-focused medical technology company. Form 8-K reports cover financial results, business updates, guidance, material events, leadership changes, board composition and Regulation FD disclosures tied to TriNav, PEDD and related oncology development activity.
Proxy materials describe shareholder voting matters, director elections, board committees, executive compensation and equity awards. The filing record also includes capital-structure disclosures for common stock and warrants, material-agreement categories, clinical or regulatory disclosure topics and risk-related information associated with commercializing PEDD infusion systems and developing investigational therapies for solid tumors.
TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its Chief Regulatory Officer on a Form 4. On November 24, 2025, the officer received 50,000 restricted stock units payable in common stock at a price of $0, with the award vesting in four equal annual installments starting November 24, 2025, subject to continued employment. The filing also discloses an employee stock option to purchase 100,000 shares of common stock at an exercise price of $5.55 per share, with one-fourth vesting on the one-year anniversary of November 24, 2025 and the remainder vesting monthly over three years, also conditioned on continued employment.
After these transactions, the officer beneficially owns 127,640 shares of common stock directly and 323,782 derivative securities, reflecting equity-based incentives tied to future service.
TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its Chief Commercial Officer on a Form 4. On November 24, 2025, the officer received 60,000 shares of common stock in the form of restricted stock units at a price of $0, bringing direct beneficial ownership of common stock to 113,854 shares after the transaction.
The same day, the officer was also granted an employee stock option to purchase 120,000 shares of common stock at an exercise price of $5.55 per share, with 408,937 derivative securities beneficially owned following the transaction. The RSUs vest in four equal annual installments starting on November 24, 2025, and the option vests over four years, with one-fourth vesting on the first anniversary of the vesting commencement date and the remainder vesting monthly through November 23, 2035, in each case subject to continued employment.
TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its chief financial officer in a Form 4 filing. On 11/24/2025, the officer received 65,000 shares of common stock as a restricted stock unit (RSU) award at a price of $0, increasing beneficial ownership of common stock to 265,000 shares held directly.
The filing also reports an employee stock option grant to buy 130,000 shares of common stock at an exercise price of $5.55 per share, expiring on 11/23/2035. The RSU award vests in four equal annual installments starting 11/24/2025, while one-fourth of the option vests on the one-year anniversary of 11/24/2025 and the remaining shares vest monthly over the following three years, in each case subject to continued employment. Following this option grant, the officer beneficially owns 668,899 derivative securities directly.
TriSalus Life Sciences, Inc. filed an S-3 shelf registration to offer up to $150,000,000 of securities, including common stock, preferred stock, debt securities, warrants, and units, which may be sold from time to time. Any specific terms and pricing will be set in a future prospectus supplement.
Net proceeds, if and when raised, are intended for general corporate purposes. The company’s Common Stock trades on Nasdaq as “TLSI,” with a closing price of $4.00 on November 10, 2025. Shares outstanding were 49,964,311 as of November 10, 2025; this is a baseline figure, not the amount being offered. TriSalus is an emerging growth company and a smaller reporting company, which allows scaled disclosure.
TriSalus Life Sciences (TLSI) reported Q3 2025 results. Revenue reached $11.566M, up from $7.349M a year ago, with gross profit of $9.660M. The company recorded a net loss of $10.811M and a net loss per share of $0.96. After preferred stock conversion-related charges, net loss attributable to common stockholders was $41.274M.
Cash and cash equivalents were $22.687M as of September 30, 2025. Total assets were $36.463M versus total liabilities of $63.188M, resulting in a stockholders’ deficit of $(26.725)M. Management disclosed substantial doubt about the company’s ability to continue as a going concern. Financing activity included drawing $10.0M under the OrbiMed facility in February, bringing long-term debt to $32.764M. Operating cash use improved year over year to $(15.528)M for the nine months, and year‑to‑date revenue rose to $31.946M from $21.170M.
TriSalus Life Sciences (TLSI) furnished a press release providing a business update and financial results for the quarter ended September 30, 2025.
The release is attached as Exhibit 99.1 and, along with the Inline XBRL cover file (Exhibit 104), is furnished and not deemed filed under Section 18, and is incorporated by reference only if specifically referenced.
TriSalus Life Sciences, Inc. reported that board member Sean Murphy resigned from the company’s Board of Directors and its Science and Technology Committee, effective September 30, 2025. The company stated that his resignation is not due to any disagreement with TriSalus on its operations, policies, or practices. The filing confirms the change is limited to his board and committee roles and provides no indication of broader operational or strategic issues.
TriSalus Life Sciences reported a performance-based grant of 248,899 employee stock options to the reporting person, exercisable at $5.11. The options become exercisable immediately if the company achieves $75 million of revenue in any consecutive 12-month period ending on or before December 31, 2027, and vesting is subject to the holder's continued service on each vesting date. If the revenue threshold is not met, the options expire on December 31, 2027. Following this reported grant, the reporting person beneficially owns 538,899 shares of common stock.
TriSalus Life Sciences, Inc. increased annual compensation for its Chief Financial Officer, David Patience, as approved by the Compensation Committee. His annual base salary rose from $450,000 under his May 27, 2025 employment agreement to $550,000, effective immediately.
In addition, the Compensation Committee granted Mr. Patience stock options to purchase 249,899 shares of common stock at an exercise price of $5.11 per share. These options vest only if the company achieves or exceeds $75 million of revenue over any twelve consecutive calendar month period ending on or before December 31, 2027, tying his equity incentive to a specific revenue performance goal.
Utmost Group PLC reports beneficial ownership of 2,000,588 shares of TriSalus Life Sciences Inc. common stock, representing 0.0529% of the outstanding class. The filing states Utmost has sole voting and dispositive power over all reported shares and identifies Lombard International Assurance SA as a subsidiary acquired by Utmost on 30/12/2024. The disclosure explains the percentage ownership fell because TriSalus’ total outstanding shares increased to 37,838,962. The filing is a Schedule 13G indicating passive reporting under the Exchange Act rules and includes Utmost’s UK address and an authorized signature by the Group CFO dated 08/11/2025.